Among over 125,000 patients, 53.6% discontinued their GLP-1 receptor agonist by 1 year, and these rates were significantly ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

New research uncovers hidden risks and surprising benefits of weight loss drugs like Ozempic, reshaping how we see these ...

Wall Street is bullish on Viking, but the company still has a lot to prove. Viking has a number of different clinical studies ...

A majority with overweight/obesity discontinue within a year, but the rate is higher among those without type 2 diabetes.

Weight loss drugs, such as those containing GLP-1 agonists like Wegovy and Mounjaro, have emerged as effective tools for ...

Unlock the potential of GLP-1 therapies! Join experts to explore cutting-edge strategies for managing cardiovascular & ...

Novo Nordisk’s NVO amycretin, which targets GLP-1 and amylin in one molecule, generated 24% placebo-adjusted weight loss in a phase ... Journal’s annual “Best on the Street” analysts ...

GLP-1 agonist medications ... With the help of a healthcare provider, you can explore the best options for weight loss, including medications, diet, and exercise. On the Klarity platform, find ...